ACLY has been proposed as the key enzyme regulating acquired CDDP resistance in ovarian cancer and, therefore, as a suitable novel target for sensitization of ovarian tumours to platinum agents [278,281]. The gene discussed is ACLY; the disease is ovarian carcinoma.